Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee

Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee

Therapies targeting the programmed cell death protein-1/programmed death-ligand 1 (PD-L1) (abbreviated as PD-(L)1) axis are a significant advancement in the treatment of many tumor types. However, many patients receiving these agents fail to respond or have an initial response followed by cancer pro...

Full description

Saved in:
Bibliographic Details
Main Authors: Charlie Garnett-Benson, Sarah Warren, Anne Monette, Alexandra Snyder, Janis M Taube, J Carl Barrett, Kurt A Schalper, Brian Topp
Format: Article
Language:English
Published: BMJ Publishing Group 2024-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/7/e009427.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items